Correction: Comparative efficacy and safety of seven Chinese patent medicines combined with SSRIs for depressive disorder: a systematic review and network meta-analysis - Scorecard - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Erratum: A Systematic Review and Network Meta-Analysis of the Efficacy and Safety of Seven Chinese Patent Medicines in Combination with SSRIs for Treating Depressive Disorders
Clinical Scorecard: Erratum: A Systematic Review and Network Meta-Analysis of the Efficacy and Safety of Seven Chinese Patent Medicines in Combination with SSRIs for Treating Depressive Disorders
At a Glance
Category
Detail
Condition
Depressive Disorders
Key Mechanisms
Combination of Chinese patent medicines with SSRIs
Target Population
Patients with depressive disorders
Care Setting
Psychiatric treatment
Key Highlights
Correction of Table 1 for clarity on SSRIs monotherapy
Mean differences (MDs) and 95% confidence intervals (CIs) presented
No change in numerical values or study conclusions
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients receiving treatment for depressive disorders
Combination therapies involving SSRIs and Chinese patent medicines
Clinical Best Practices
Ensure clarity in comparative efficacy tables
Use SSRIs monotherapy as a common reference in analyses
